1-3 of 3
William Kisseberth, DVM, PhD
Close
Sort by
Journal Articles

Exploring PRMT5 As a Potential Therapeutic Target in Canine Lymphomas

Kyle Renaldo, DVM, MS, Shelby Sloan, BS, JiHyun Chung, PhD, Lindsay Courtney, BS, Konstantin Shilo, MD, William Kisseberth, DVM, PhD, Robert A Baiocchi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4182.
https://doi.org/10.1182/blood-2018-99-119115
Published: 2018
Journal Articles

Evaluation Of The Novel, Orally Bioavailable Selective Inhibitor Of Nuclear Export (SINE) Verdinexor (KPT-335) In Spontaneous Canine Cancer: Results Of Phase I and Phase II Clinical Trials

Cheryl London, DVM, PhD, Luis feo Bernabe, DVM, Sandra Barnard, BVSc, William Kisseberth, DVM, PhD, Antonella Borgatti, DVM, Michael Henson, DVM, Heather Wilson, DVM, Kiersten Jensen, MS, Daisuke Ito, DVM PhD, Jaime Modiano, DVM PhD, Misty Bear, MS, Michael Pennell, Jean-Richard Saint-Martin, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5149.
https://doi.org/10.1182/blood.V122.21.5149.5149
Published: 2013
Journal Articles

Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin's Lymphomas (NHL)

Sharon Shacham, PhD MBA, Sandra Barnard, BVSc, William Kisseberth, DVM, PhD, Daisuke Ito, DVM PhD, Kiersten Jensen, Antonella Borgotti, DVM MS, Michael Henson, DVM PhD, Heather Wilson, DVM, Dilara McCauley, PhD, Jaime Modiano, DVM PhD, Michael Kauffman, MD, PhD, Cheryl London, DVM PhD
Journal: Blood
Blood (2012) 120 (21): 161.
https://doi.org/10.1182/blood.V120.21.161.161
Published: 2012